Jon E. Angell

Array ( [id] => 19135569 [patent_doc_number] => 11970499 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-04-30 [patent_title] => Pyrazolo[1,5-c]pyrimidine compounds as CK2 inhibitors [patent_app_type] => utility [patent_app_number] => 18/395130 [patent_app_country] => US [patent_app_date] => 2023-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10287 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18395130 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19332571 [patent_doc_number] => 20240247001 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-25 [patent_title] => 2,6,9-TRISUBSTITUTED PURINES [patent_app_type] => utility [patent_app_number] => 18/541006 [patent_app_country] => US [patent_app_date] => 2023-12-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 64023 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18541006 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19318225 [patent_doc_number] => 20240239767 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-18 [patent_title] => PCSK9 INHIBITORS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/539471 [patent_app_country] => US [patent_app_date] => 2023-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56166 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18539471 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19343510 [patent_doc_number] => 20240252473 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-01 [patent_title] => Sulfoximines as inhibitors of NaV1.8 [patent_app_type] => utility [patent_app_number] => 18/540502 [patent_app_country] => US [patent_app_date] => 2023-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46890 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 327 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18540502 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20014288 [patent_doc_number] => 20250152510 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-05-15 [patent_title] => LIPIDS AND LIPID NANOPARTICLE FORMULATIONS [patent_app_type] => utility [patent_app_number] => 18/532785 [patent_app_country] => US [patent_app_date] => 2023-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22472 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 331 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18532785 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19050753 [patent_doc_number] => 20240092722 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-21 [patent_title] => BETA-HYDROXYBUTYRATE WITH PURE BIOBASED CARBON CONTENT AND METHODS FOR PRODUCING THE SAME [patent_app_type] => utility [patent_app_number] => 18/517037 [patent_app_country] => US [patent_app_date] => 2023-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4387 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18517037 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19202754 [patent_doc_number] => 20240174653 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-30 [patent_title] => SOLUBLE GUANYLATE CYCLATE ACTIVATORS FOR TREATING SYSTEMIC SCLEROSIS [patent_app_type] => utility [patent_app_number] => 18/386267 [patent_app_country] => US [patent_app_date] => 2023-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19243 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 194 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18386267 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20201514 [patent_doc_number] => 12404283 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-02 [patent_title] => c-MYC mRNA translation modulators and uses thereof in the treatment of cancer [patent_app_type] => utility [patent_app_number] => 18/868756 [patent_app_country] => US [patent_app_date] => 2023-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 5 [patent_no_of_words] => 83443 [patent_no_of_claims] => 38 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 134 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18868756 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19018980 [patent_doc_number] => 20240075151 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-07 [patent_title] => CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS [patent_app_type] => utility [patent_app_number] => 18/202880 [patent_app_country] => US [patent_app_date] => 2023-05-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35640 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18202880 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19564726 [patent_doc_number] => 12139487 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-11-12 [patent_title] => Compounds and uses thereof [patent_app_type] => utility [patent_app_number] => 18/315526 [patent_app_country] => US [patent_app_date] => 2023-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 13 [patent_no_of_words] => 72394 [patent_no_of_claims] => 102 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18315526 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19065637 [patent_doc_number] => 20240100063 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-28 [patent_title] => COMBINATION THERAPY OF PD-1 AXIS BINDING ANTAGONISTS AND LRRK2 INHITIBORS [patent_app_type] => utility [patent_app_number] => 18/303802 [patent_app_country] => US [patent_app_date] => 2023-04-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41128 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18303802 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19793281 [patent_doc_number] => 12234210 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-02-25 [patent_title] => Synthesis of nirogacestat [patent_app_type] => utility [patent_app_number] => 18/304202 [patent_app_country] => US [patent_app_date] => 2023-04-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9252 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 115 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18304202 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19368288 [patent_doc_number] => 12060358 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-08-13 [patent_title] => Orally bioavailable, brain-penetrant compound with selectivity for the cannabinoid type 2 receptor with potential use towards visceral pain management and neurodegenerative disorders [patent_app_type] => utility [patent_app_number] => 18/191247 [patent_app_country] => US [patent_app_date] => 2023-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 8 [patent_no_of_words] => 27063 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18191247 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19430899 [patent_doc_number] => 20240299397 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-12 [patent_title] => REHYDRATION COMPOSITION AND METHOD OF USE [patent_app_type] => utility [patent_app_number] => 18/119776 [patent_app_country] => US [patent_app_date] => 2023-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11452 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18119776 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18610769 [patent_doc_number] => 20230277499 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-07 [patent_title] => FORMS OF ATICAPRANT [patent_app_type] => utility [patent_app_number] => 18/178961 [patent_app_country] => US [patent_app_date] => 2023-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33615 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18178961 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18595942 [patent_doc_number] => 20230270732 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-31 [patent_title] => BLOCKADE OF CHEMOKINE (C-C MOTIF) RECEPTOR 2 DURING FLUID RESUSCITATION [patent_app_type] => utility [patent_app_number] => 18/115058 [patent_app_country] => US [patent_app_date] => 2023-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9918 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18115058 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20262910 [patent_doc_number] => 12433878 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-07 [patent_title] => Uses of bupivacaine multivesicular liposomes as stellate ganglion block [patent_app_type] => utility [patent_app_number] => 18/171831 [patent_app_country] => US [patent_app_date] => 2023-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 0 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 121 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18171831 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20270691 [patent_doc_number] => 12440455 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-14 [patent_title] => Methods of administering cannabinoids [patent_app_type] => utility [patent_app_number] => 18/169155 [patent_app_country] => US [patent_app_date] => 2023-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 3164 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 123 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18169155 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19457636 [patent_doc_number] => 12098116 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-09-24 [patent_title] => Crystalline prostacyclin (IP) receptor agonist and uses thereof [patent_app_type] => utility [patent_app_number] => 18/169016 [patent_app_country] => US [patent_app_date] => 2023-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 35 [patent_no_of_words] => 18606 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18169016 [rel_patent_id] =>[rel_patent_doc_number] =>)